PharmaTher Holdings Ltd. (PHRRF)
USD 0.16
(-0.62%)
USD 0.16
(-0.62%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | 1422.00 | 1777.00 | 355.00 | - |
| Gross Profit | - | -1422.00 | -1777.00 | -355.00 | - |
| Operating Expenses | 3.04 Million | 4.01 Million | 4.1 Million | 2.81 Million | 23.81 Thousand |
| Selling, General and Administrative Expenses | 904.36 Thousand | 941.72 Thousand | 1.35 Million | 1.67 Million | 23.81 Thousand |
| Research and Development Expenses | 2.13 Million | 3.01 Million | 2.6 Million | 751.53 Thousand | - |
| Other Expenses | - | 24.98 Thousand | - | - | - |
| Cost and Expenses | 3.04 Million | 4.01 Million | 4.1 Million | 2.81 Million | 23.81 Thousand |
| Operating Income | -3.04 Million | -1.38 Million | -3.96 Million | -8.52 Million | -23.82 Thousand |
| Interest Expense | - | - | - | - | - |
| Income Tax Expense | - | 2.42 Million | -225.05 Thousand | 225.05 Thousand | -142.90 |
| Earnings before Tax | -3.11 Million | -6.41 Million | -4.23 Million | 2.88 Million | -23.81 Thousand |
| Net Income | -3.11 Million | -6.41 Million | -4.01 Million | 2.66 Million | -23.81 Thousand |
| Earnings Per Share Basic | -0.04 | -0.07 | -0.05 | 0.04 | -0.00 |
| Earnings Per Share Diluted | -0.04 | -0.07 | -0.05 | 0.04 | -0.00 |
| Weighted Average Shares Outstanding | 88.22 Million | 88.16 Million | 81.1 Million | 64.55 Million | 34.08 Million |
| Weighted Average Shares Outstanding (Diluted) | 88.22 Million | 88.16 Million | 81.1 Million | 73.26 Million | 34.08 Million |
| Gross Margin | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - |
| Profit Margin | - | - | - | - | - |
| EBITDA | -3.04 Million | -3.95 Million | -3.95 Million | -2.42 Million | - |
| Earnings Before Tax Margin | - | - | - | - | - |
| Breakdown | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | 356.00 | 355.00 | 356.00 | 1422.00 |
| Gross Profit | - | - | -356.00 | -355.00 | -356.00 | -1422.00 |
| Operating Expenses | 386.27 Thousand | 421.65 Thousand | 915.43 Thousand | 1.35 Million | 1.13 Million | 4.01 Million |
| Selling, General and Administrative Expenses | 194.48 Thousand | 214.02 Thousand | 216.8 Thousand | 279.05 Thousand | 278.36 Thousand | - |
| Research and Development Expenses | 191.78 Thousand | 200.17 Thousand | 681.01 Thousand | 1.06 Million | 850.42 Thousand | - |
| Other Expenses | - | 7457.00 | - | - | - | 24.98 Thousand |
| Cost and Expenses | 386.27 Thousand | 421.65 Thousand | 915.43 Thousand | 1.35 Million | 1.13 Million | 4.01 Million |
| Operating Income | -386.27 Thousand | -414.20 | -735.43 Thousand | -1.34 Million | -600.18 Thousand | -1.38 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | 382.7 Thousand | 129.42 Thousand | -54.96 Thousand | 485.51 Thousand | 2.42 Million |
| Earnings before Tax | -360.59 Thousand | -362.76 Thousand | -1.05 Million | -1.33 Million | -1.59 Million | -6.41 Million |
| Net Income | -360.59 Thousand | -362.76 Thousand | -1.05 Million | -1.33 Million | -1.59 Million | -6.41 Million |
| Earnings Per Share Basic | -0.00 | -0.00 | -0.01 | -0.02 | -0.02 | - |
| Earnings Per Share Diluted | -0.00 | -0.00 | -0.01 | -0.02 | -0.02 | - |
| Weighted Average Shares Outstanding | 88.4 Million | 88.16 Million | 88.16 Million | 88.16 Million | 88.16 Million | 88.16 Million |
| Weighted Average Shares Outstanding (Diluted) | 88.39 Million | 88.16 Million | 88.16 Million | 88.16 Million | 88.16 Million | 88.16 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -386.27 Thousand | -448.32 Thousand | -735.07 Thousand | -1.34 Million | -599.82 Thousand | - |
| Earnings Before Tax Margin | - | - | - | - | - | - |
NSRCF
SHOORA
DC-A
BEC
APCOTEXIND
688767